Veracyte Announces Third Quarter 2026 Financial Results
Grew total revenue to $151.8 million and testing revenue to $146.4 million, representing 15% year-over-year growth
Announces $100 million share repurchase program SOUTH SAN FRANCISCO, Calif., November 4, 2026 --- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2026.
“We delivered solid third quarter results supported by strong profitability and cash generation,” said Marc Stapley, chief executive officer of Veracyte. “Afirma outperformed, while Decipher Prostate volume was below our expectations. We remain confident in the long-term outlook of our business and expect a number of evidence-based catalysts to support growth in our core franchises while also advancing our breast and bladder strategies. As we execute on these opportunities, our differentiated financial profile enables us to continue investing in the business to drive long-term growth.”
For the three-month period ended September 30, 2026, as compared to the same period in 2025: • Increased total revenue by 15% to $151.8 million and testing revenue by 15% to $146.4 million, driven by Decipher Prostate growth of 12% to $92.3 million and Afirma growth of 19% to $51.5 million.
• Increased total volume by 15% to 52,744 tests and testing volume by 13% to 49,498 tests, driven by approximately 29,900 Decipher Prostate tests, as well as approximately 19,100 Afirma tests. Volume for each test grew 12% year-over-year.
• Increased product revenue by 40% to $4.6 million, driven by strong adoption of Prosigna IVD following the release of the phase III OPTIMA trial results at ASCO.
• Recorded GAAP net income of $31.5 million, or 20.8% of revenue, and delivered adjusted EBITDA of $41.2 million, or 27.2% o f revenue.
• Generated $40.3 million of cash from operations to end the quarter with $370.5 million of cash, cash equivalents, and short-term investments as of September 30, 2026.
• Acquired Convergent Genomics, Inc., expanding our urology portfolio with a urinary tumor DNA testing platform to help guide bladder cancer care across the patient journey.
• Secured Medicare reimbursement for our Prosigna Breast Risk of Recurrence (ROR) test in the U.S. for eligible patients diagnosed with early-stage hormone- receptor positive (HR+) breast cancer.
• Further expanded the clinical evidence of the Decipher Prostate test, with new predictive evidence supporting its use with treatment intensification decisions across intermediate-risk and very high-risk prostate cancer.
• Surpassed a key milestone, with more than 1 million patients served to date with Veracyte's tests.
• Announced that the Board of Directors has authorized a share repurchase program for up to $100 million of common stock.
A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Note Regarding Use of Non-GAAP Financial Measures."
Total revenue for the third quarter of 2026 was $151.8 million, an increase of 15% compared to $131.9 million reported in the third quarter of 2025. Testing revenue was $146.4 million, an increase of 15% compared to $127.8
million in the third quarter of 2025, driven by growth in our Decipher Prostate and Afirma tests. Product revenue was $4.6 million, an increase of 40% compared to $3.3 million in the third quarter of 2025, driven by strong adoption of Prosigna IVD following the release of the phase III OPTIMA trial results at ASCO. Biopharmaceutical and other revenue was $0.7 million, compared to $0.8 million in the third quarter of 2025.
Total gross margin for the third quarter of 2026 was 71%, compared to 69% in the third quarter of 2025. Non-GAAP gross margin was 74%, compared to 73% in the third quarter of 2025.
Operating expenses were $90.5 million for the third quarter of 2026 compared to $68.3 million in the third quarter of 2025. Non-GAAP operating expenses grew 24% to $72.9 million compared to $58.6 million in the third quarter of 2025.
GAAP Net income for the third quarter of 2026 was $31.5 million, an increase of $12.4 million compared to the third quarter of 2025. Diluted net earnings per common share was $0.38, an improvement of $0.14 compared to the third quarter of 2025. Non-GAAP diluted net earnings per common share was $0.51, flat compared to the third quarter of 2025. Net cash provided by operating activities in the first nine months of 2026 was $121.3 million, an improvement of $37.6 million compared to the same period in 2025.
Adjusted EBITDA for the third quarter of 2026 was $41.2 million, an improvement of 4% compared to the third quarter of 2025, representi ng 27.2% of revenue.
Veracyte now expects 2026 total revenue guidance of $590 million to $593 million, representing 14% to 15% growth, compared to prior guidance of $590 million to $596 million. This reflects testing revenue of $571 million to $573 million, representing 16% growth, compared to prior guidance of $576 million to $582 million, with minimal revenue contribution from recently launched tests. Further, the company continues to expect adjusted EBITDA margin of greater than 26% for 2026.
The company is unable to provide a quantitative reconciliation of expected adjusted EBITDA margin to expected GAAP net income margin, the most directly comparable forward-looking GAAP measure without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, that are dependent on various factors, are out of the company’s control, or that cannot be reasonably predicted. Such adjustments include, but are not limited to, acquisition-related expenses, and other adjustments. Any associated estimate of these items and their impact on GAAP performance for the guidance period could vary materially. For more information on the non-GAAP financial measures, please refer to the section titled “Note Regarding Use of Non-GAAP Financial Measures” at the end of this press release.
Veracyte announced today that its Board of Directors has authorized a share repurchase program for up to $100 million of its common stock. Under the repurchase program, the company may repurchase shares through open market purchases, privately negotiated transactions or by other methods from time to time. Any open market repurchases will be structured to comply with applicable federal securities laws, including the pricing and volume requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing, manner, price, and amount of any repurchases will be determined at the company's discretion based on a variety of factors, including market conditions, the trading price of the company's common stock, the company's financial condition and results of operations, capital requirements, general business conditions, alternative investment opportunities, and other factors the company deems relevant. The repurchase program does not obligate the company to acquire any specific number of shares, may be modified, suspended, or discontinued at any time without prior notice at the discretion of the Board of Directors, and will expire after 12 months. The company currently expects to fund the repurchase program from available cash and cash equivalents.
Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media- server.com/mmc/p/kgcmbvpd. The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.
Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company’s molecular tests assess the unique biology of each patient’s tumor to help clinicians answer essential questions about cancer care. Veracyte’s Diagnostics Platform combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued innovation and pipeline development . The company’s portfolio includes the Afirma® Genomic Sequencing Classifier test , Decipher® Bladder Genomic Classifier test , Decipher® Prostate Genomic Classifier test , Prosigna® Breast Risk of Recurrence test , and the TrueMRD™ Monitoring Test for MIBC . For more information, visit Veracyte’s website or follow the company on LinkedIn or X (Twitter) .
This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to our 2026 financial and operating results; our share repurchase program, including the timing, amount and source of funds for any
repurchases of shares; and our intentions with respect to the development, launch, commercialization, adoption, and reimbursement of our tests and products. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “could,” “would,” “will,” “enable,” “positioned,” “offers,” “designed,” “ultimately,” “strategic,” “outlook,” “guidance,” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to launch, commercialize and receive reimbursement for our products; our ability to execute on our business strategies relating to our acquisitions, including C2i Genomics and Convergent Genomics, Inc., integration of the business and the realization of expected benefits and synergies; our ability to demonstrate the validity and utility of our genomic tests and biopharma and other offerings; our ability to continue executing on our business plan; our ability to continue to scale our global operations and enhance our internal control environment; the impact of the war in Ukraine and other regional conflicts on European economies; the impact of foreign currency fluctuations, volatile interest rates, inflation, the impact of legislation and policies enacted by the current U.S. administration; turmoil in the global banking and finance system; the ongoing conflict in the Middle East; and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise.
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release and the accompanying tables contain, and reference certain non-GAAP results including non-GAAP gross margin, non-GAAP operating expenses, adjusted EBITDA, adjusted EBITDA as a percentage of revenue (also referred to as adjusted EBITDA margin), non-GAAP net income, and non-GAAP earnings per share (EPS) and non-GAAP weighted average shares outstanding. These non-GAAP financial measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.
We use non-GAAP financial measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures. However, the non-GAAP financial measures we present may be different from those used by other companies, including similarly titled measures.
We compute these non-GAAP measures by adjusting the applicable GAAP measure to remove the impact of certain recurring and non-recurring charges and gains and to adjust for the impact of income tax items related to such adjustments to our GAAP financial statements. In particular, we exclude amortization of acquired intangible assets,
acquisition-related expenses relating to our acquisitions of Decipher Biosciences, HalioDx and C2i Genomics, impairment charges associated with the nCounter license and other biopharmaceutical services related to HalioDx intangible assets, all stock-based compensation and certain costs related to restructuring from all of our non-GAAP financial measures as well as depreciation and income tax items from our adjusted EBITDA and adjusted EBITDA as a percentage of revenue. Beginning in the second quarter of 2024, we changed our non-GAAP policy to exclude all stock-based compensation to align with our peers and we have also excluded all stock-based compensation from our prior period non-GAAP financial measures. Management has excluded the effects of these items in non-GAAP financial measures to help investors gain a better understanding of the core operating results and future prospects of the company, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts. The company encourages investors to carefully consider its results under GAAP, together with its supplemental non‐GAAP information and the reconciliation between these presentations. See “Reconciliation of U.S. GAAP to Non-GAAP Financial Measures” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.
1. Cost of revenue, research and development, sales and marketing and general and administrative expenses include the following stock-based compensation related expenses:
VERACYTE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) September 30, December 31, Assets 2026 2025 Current assets: (Unaudited) (See Note 1) ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 199,828 $ 362,578 equivalents Short-term 170,704 50,311 investments Accounts receivable 56,788 44,660 Supplies 25,818 20,546 Prepaid expenses and other current 14,740 10,281 assets Total current assets 467,878 488,376 Property, plant and 24,870 22,192 equipment, net Right-of-use assets, 35,097 36,599 operating leases Intangible assets, 184,883 89,148 net Goodwill 855,575 767,154 Restricted cash 1,646 1,648 Other assets 3,307 902 Total assets $ 1,573,256 $ 1,406,019 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 9,710 $ 4,593 Accrued liabilities 60,087 48,801 Current portion of 864 1,160 deferred revenue Current portion of acquisition-related 6,734 1,332 contingent consideration Current portion of operating lease 6,814 4,051 liabilities Total current 84,209 59,937 liabilities Deferred tax 1,616 646 liabilities Acquisition-related contingent 17,245 257 consideration, net of current portion Operating lease liabilities, net of 33,922 35,603 current portion Other liabilities 3,000 — Total liabilities 139,992 96,443 Total stockholders’ 1,433,264 1,309,576 equity Total liabilities and stockholders’ $ 1,573,256 $ 1,406,019 equity 1. The condensed consolidated balance sheet at December 31, 2025 has been derived from the audited financial statements at that date included in the company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 26, 2026.
VERACYTE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Nine Months Ended (In thousands) September 30, Operating activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 85,700 $ 25,204 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 16,247 16,117 amortization Loss on disposal of property, plant and 367 15 equipment Stock-based 40,806 32,700 compensation Deferred income taxes -11,599 -13 Noncash lease expense 2,088 2,289 Revaluation of acquisition-related -1,110 -2,713 contingent consideration Effect of foreign -23 -3,845 currency on operations Amortization of discount on short-term -2,380 -2,619 investments Impairment loss — 20,505 Non-cash loss on deconsolidation of — 3,863 subsidiary Changes in operating assets and liabilities: Accounts receivable -11,963 -3,858 Supplies -3,435 -2,642 Prepaid expenses and other current -4,112 -6,416 assets Other assets -771 331 Operating lease 496 -1,681 liabilities Accounts payable 5,522 -547 Accrued liabilities 5,466 7,034 and deferred revenue Net cash provided by operating 121,299 83,724 activities Investing activities Business acquisitions, net of cash -153,190 — acquired Purchase of short-term -234,997 -99,998 investments Proceeds from maturity of short-term 116,984 102,116 investments Issuance of loan -1,622 — receivable Purchases of property, plant and -8,155 -5,897 equipment Net cash used in -280,980 -3,779 investing activities Financing activities Payment of taxes on vested restricted -17,462 -14,645 stock units Proceeds from the exercise of common stock options and 14,493 10,572 employee stock purchases Net cash used in -2,969 -4,073 financing activities (Decrease) increase in cash, cash -162,650 75,872 equivalents and restricted cash Effect of foreign currency on cash, cash -102 707 equivalents and restricted cash Net (decrease) increase in cash, cash -162,752 76,579 equivalents and restricted cash Cash, cash equivalents and restricted 364,226 240,631 cash at beginning of period Cash, cash equivalents and restricted $ 201,474 $ 317,210 cash at end of period
CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Unaudited) (In thousands) September 30, December 31, 2026 2025 Cash and cash equivalents $ 199,828 $ 362,578 Restricted cash 1,646 1,648 Total cash, cash equivalents and $ 201,474 $ 364,226 restricted cash
1.Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with the acquisition of Convergent Genomics, Inc. ("Convergent") ($1.7 million) partially offset with contingent consideration related to the NanoString Technologies, Inc. ("NanoString") transaction ($0.4 million). For the three months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to NanoString and contingent consideration associated with the acquisition of C2i Genomics. For the nine months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with the acquisition of Convergent ($1.7 million) partially offset with NanoString contingent consideration ($1.1 million). For the nine months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics ($1.6 million) partially offset by NanoString contingent consideration ($1.0 million). 2.For the three months ended September 30, 2026, adjustments consist primarily of expenses related to legal proceedings ($3.2 million), partially offset by the impact of Non-GAAP adjustments on IT/Facilities allocations ($0.3 million). For the three months ended September 30, 2025, adjustments primarily include a vendor legal settlement ($2.8 million) partially offset by expenses related to the restructuring and liquidation proceedings of Veracyte SAS ($1.0 million) and other legal proceedings ($0.5 million). For the nine months ended September 30, 2026, adjustments consist primarily of expenses related to legal proceedings ($4.9 million), expenses related to the assessment of licensing and strategic investments ($3.0 million), and expenses related to the liquidation proceedings of Veracyte SAS ($0.3 million), partially offset by the impact of Non-GAAP adjustments on IT/Facilities allocations ($0.9 million). For the nine months ended September 30, 2025, adjustments include additional expenses related to Veracyte SAS impairment loss ($20.5 million) and related to the restructuring and liquidation proceedings of Veracyte SAS ($8.0 million), partially offset by adjustments related to restructuring costs ($0.1 million).
1.Includes transaction-related expenses as well as post-combination compensation expenses. For the three months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with the acquisition activities ($1.9 million), partially offset by contingent consideration related to the NanoString transaction ($0.4 million). For the three months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with contingent consideration related to NanoString and contingent consideration associated with the acquisition of C2i Genomics. For the nine months ended September 30, 2026, adjustments consist primarily of transaction-related expenses associated with the acquisition activities ($1.9 million), partially offset with NanoString contingent consideration ($1.1 million). For the nine months ended September 30, 2025, adjustments consist primarily of transaction-related expenses associated with the acquisition of C2i Genomics ($1.6 million) partially offset by NanoString contingent consideration ($1.0 million). 2.Includes interest income and income related to research tax credits. 3.For the three months ended September 30, 2026, adjustments consist primarily of expenses related to legal proceedings ($3.2 million). For the three months ended September 30, 2025, adjustments primarily include expenses related to the exclusion of unrealized loss related to Veracyte SAS deconsolidation ($6.7 million), the exclusion of unrealized loss associated with foreign exchange impact on stock-based compensation and intercompany loans ($1.3 million), the restructuring and liquidation proceedings of Veracyte SAS ($2.4 million), and other legal proceedings ($0.5 million), partially offset by vendor legal settlement ($2.8 million). For the nine months ended September 30, 2026, adjustments primarily include expenses related to legal proceedings ($4.9 million), expenses related to the assessment of licensing and strategic investments ($3.0 million), expenses related to the liquidation proceedings of Veracyte SAS ($0.3 million), and losses related to asset disposition ($0.4 million), partially offset by adjustments related to the restructuring and liquidation proceedings of Veracyte SAS ($4.2 million). For the nine months ended September 30, 2025, adjustments include additional expenses related to Veracyte SAS impairment loss ($20.5 million) and Veracyte SAS investment review ($8.0 million), partially offset by adjustments related to restructuring costs ($0.1 million) and additional exclusion of unrealized gains associated with foreign exchange impacts on stock-based compensation and intercompany loans ($3.6 million). 4.Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed. 5.In those periods in which GAAP net (loss) income is negative and non-GAAP net (loss) income is positive, non-GAAP diluted weighted average shares outstanding includes potentially dilutive common shares from equity awards as determined using the treasury stock method.
Full text with the tables
Exhibit 99.1
Veracyte Announces Third Quarter 2026 Financial Results
Grew total revenue to $151.8 million and testing revenue to $146.4 million,
representing 15% year-over-year growth
Announces $100 million share repurchase program
SOUTH SAN FRANCISCO, Calif., November 4, 2026 --- Veracyte, Inc. (Nasdaq: VCYT),
a leading cancer diagnostics company, today announced financial results for the
third quarter ended September 30, 2026.
“We delivered solid third quarter results supported by strong profitability and
cash generation,” said Marc Stapley, chief executive officer of Veracyte.
“Afirma outperformed, while Decipher Prostate volume was below our expectations.
We remain confident in the long-term outlook of our business and expect a number
of evidence-based catalysts to support growth in our core franchises while also
advancing our breast and bladder strategies. As we execute on these
opportunities, our differentiated financial profile enables us to continue
investing in the business to drive long-term growth.”
Key Financial Highlights
For the three-month period ended September 30, 2026, as compared to the same
period in 2025:
• Increased total revenue by 15% to $151.8 million and testing revenue by 15% to
$146.4 million, driven by Decipher Prostate growth of 12% to $92.3 million and
Afirma growth of 19% to $51.5 million.
• Increased total volume by 15% to 52,744 tests and testing volume by 13% to
49,498 tests, driven by approximately 29,900 Decipher Prostate tests, as well as
approximately 19,100 Afirma tests. Volume for each test grew 12% year-over-year.
• Increased product revenue by 40% to $4.6 million, driven by strong adoption of
Prosigna IVD following the release of the phase III OPTIMA trial results at
ASCO.
• Recorded GAAP net income of $31.5 million, or 20.8% of revenue, and delivered
adjusted EBITDA of $41.2 million, or 27.2% o f revenue.
• Generated $40.3 million of cash from operations to end the quarter with $370.5
million of cash, cash equivalents, and short-term investments as of September
30, 2026.
Key Business Highlights
• Acquired Convergent Genomics, Inc., expanding our urology portfolio with a
urinary tumor DNA testing platform to help guide bladder cancer care across the
patient journey.
• Secured Medicare reimbursement for our Prosigna Breast Risk of Recurrence
(ROR) test in the U.S. for eligible patients diagnosed with early-stage hormone-
receptor positive (HR+) breast cancer.
• Further expanded the clinical evidence of the Decipher Prostate test, with new
predictive evidence supporting its use with treatment intensification decisions
across intermediate-risk and very high-risk prostate cancer.
• Surpassed a key milestone, with more than 1 million patients served to date
with Veracyte's tests.
• Announced that the Board of Directors has authorized a share repurchase
program for up to $100 million of common stock.
A reconciliation of GAAP to non-GAAP financial measures has been provided in the
tables included in this press release. An explanation of these measures is also
included below under the heading "Note Regarding Use of Non-GAAP Financial
Measures."
Third Quarter 2026 Financial Results
Total revenue for the third quarter of 2026 was $151.8 million, an increase of
15% compared to $131.9 million reported in the third quarter of 2025. Testing
revenue was $146.4 million, an increase of 15% compared to $127.8
million in the third quarter of 2025, driven by growth in our Decipher Prostate
and Afirma tests. Product revenue was $4.6 million, an increase of 40% compared
to $3.3 million in the third quarter of 2025, driven by strong adoption of
Prosigna IVD following the release of the phase III OPTIMA trial results at
ASCO. Biopharmaceutical and other revenue was $0.7 million, compared to $0.8
million in the third quarter of 2025.
Total gross margin for the third quarter of 2026 was 71%, compared to 69% in the
third quarter of 2025. Non-GAAP gross margin was 74%, compared to 73% in the
third quarter of 2025.
Operating expenses were $90.5 million for the third quarter of 2026 compared to
$68.3 million in the third quarter of 2025. Non-GAAP operating expenses grew 24%
to $72.9 million compared to $58.6 million in the third quarter of 2025.
GAAP Net income for the third quarter of 2026 was $31.5 million, an increase of
$12.4 million compared to the third quarter of 2025. Diluted net earnings per
common share was $0.38, an improvement of $0.14 compared to the third quarter of
2025. Non-GAAP diluted net earnings per common share was $0.51, flat compared to
the third quarter of 2025. Net cash provided by operating activities in the
first nine months of 2026 was $121.3 million, an improvement of $37.6 million
compared to the same period in 2025.
Adjusted EBITDA for the third quarter of 2026 was $41.2 million, an improvement
of 4% compared to the third quarter of 2025, representi ng 27.2% of revenue.
2026 Financial Outlook
Veracyte now expects 2026 total revenue guidance of $590 million to $593
million, representing 14% to 15% growth, compared to prior guidance of $590
million to $596 million. This reflects testing revenue of $571 million to $573
million, representing 16% growth, compared to prior guidance of $576 million to
$582 million, with minimal revenue contribution from recently launched tests.
Further, the company continues to expect adjusted EBITDA margin of greater than
26% for 2026.
The company is unable to provide a quantitative reconciliation of expected
adjusted EBITDA margin to expected GAAP net income margin, the most directly
comparable forward-looking GAAP measure without unreasonable effort, because of
the inherent difficulty in accurately forecasting the occurrence and financial
impact of the various adjusting items necessary for such reconciliations that
have not yet occurred, that are dependent on various factors, are out of the
company’s control, or that cannot be reasonably predicted. Such adjustments
include, but are not limited to, acquisition-related expenses, and other
adjustments. Any associated estimate of these items and their impact on GAAP
performance for the guidance period could vary materially. For more information
on the non-GAAP financial measures, please refer to the section titled “Note
Regarding Use of Non-GAAP Financial Measures” at the end of this press release.
Share Repurchase Program
Veracyte announced today that its Board of Directors has authorized a share
repurchase program for up to $100 million of its common stock. Under the
repurchase program, the company may repurchase shares through open market
purchases, privately negotiated transactions or by other methods from time to
time. Any open market repurchases will be structured to comply with applicable
federal securities laws, including the pricing and volume requirements of Rule
10b-18 under the Securities Exchange Act of 1934, as amended. The timing,
manner, price, and amount of any repurchases will be determined at the company's
discretion based on a variety of factors, including market conditions, the
trading price of the company's common stock, the company's financial condition
and results of operations, capital requirements, general business conditions,
alternative investment opportunities, and other factors the company deems
relevant. The repurchase program does not obligate the company to acquire any
specific number of shares, may be modified, suspended, or discontinued at any
time without prior notice at the discretion of the Board of Directors, and will
expire after 12 months. The company currently expects to fund the repurchase
program from available cash and cash equivalents.
Conference Call and Webcast Details
Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time
to discuss the company's financial results and provide a general business
update. The conference call will be webcast live from the company’s website and
will be available via the following link: https://edge.media-
server.com/mmc/p/kgcmbvpd. The webcast should be accessed 10 minutes prior to
the conference call start time. A replay of the webcast will be available for
one year following the conclusion of the live broadcast and will be accessible
on the company’s website at https://investor.veracyte.com/events-presentations.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company with a vision to
transform cancer care for patients around the world. The company’s molecular
tests assess the unique biology of each patient’s tumor to help clinicians
answer essential questions about cancer care. Veracyte’s Diagnostics Platform
combines broad genomic and clinical data, advanced bioinformatics and AI, and a
powerful evidence-generation engine to support continued innovation and pipeline
development . The company’s portfolio includes the Afirma® Genomic Sequencing
Classifier test , Decipher® Bladder Genomic Classifier test , Decipher® Prostate
Genomic Classifier test , Prosigna® Breast Risk of Recurrence test , and the
TrueMRD™ Monitoring Test for MIBC . For more information, visit Veracyte’s
website or follow the company on LinkedIn or X (Twitter) .
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not
limited to our statements related to our plans, objectives, and expectations
(financial and otherwise), including with respect to our 2026 financial and
operating results; our share repurchase program, including the timing, amount
and source of funds for any
repurchases of shares; and our intentions with respect to the development,
launch, commercialization, adoption, and reimbursement of our tests and
products. Forward-looking statements can be identified by words such as:
“appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,”
“could,” “would,” “will,” “enable,” “positioned,” “offers,” “designed,”
“ultimately,” “strategic,” “outlook,” “guidance,” and similar references to
future periods. Actual results may differ materially from those projected or
suggested in any forward-looking statements. These statements involve risks and
uncertainties, which could cause actual results to differ materially from our
predictions, and include, but are not limited to: our ability to launch,
commercialize and receive reimbursement for our products; our ability to execute
on our business strategies relating to our acquisitions, including C2i Genomics
and Convergent Genomics, Inc., integration of the business and the realization
of expected benefits and synergies; our ability to demonstrate the validity and
utility of our genomic tests and biopharma and other offerings; our ability to
continue executing on our business plan; our ability to continue to scale our
global operations and enhance our internal control environment; the impact of
the war in Ukraine and other regional conflicts on European economies; the
impact of foreign currency fluctuations, volatile interest rates, inflation, the
impact of legislation and policies enacted by the current U.S. administration;
turmoil in the global banking and finance system; the ongoing conflict in the
Middle East; and the performance and utility of our tests in the clinical
environment. Additional factors that may impact these forward-looking statements
can be found under the caption “Risk Factors” in our Annual Report on Form 10-K
filed on February 26, 2026, as well as in other documents that we may file from
time to time with the Securities and Exchange Commission. Copies of these
documents, when available, may be found in the Investors section of our website
at investor.veracyte.com. These forward-looking statements speak only as of the
date hereof and, except as required by law, we specifically disclaim any
obligation to update these forward-looking statements, whether as a result of
new information, future events or otherwise.
Note Regarding Use of Non-GAAP Financial Measures
In addition to the financial measures prepared in accordance with generally
accepted accounting principles (GAAP), this press release and the accompanying
tables contain, and reference certain non-GAAP results including non-GAAP gross
margin, non-GAAP operating expenses, adjusted EBITDA, adjusted EBITDA as a
percentage of revenue (also referred to as adjusted EBITDA margin), non-GAAP net
income, and non-GAAP earnings per share (EPS) and non-GAAP weighted average
shares outstanding. These non-GAAP financial measures are not meant to be
considered superior to or a substitute for financial measures calculated in
accordance with GAAP, and investors are cautioned that there are material
limitations associated with the use of non-GAAP financial measures as an
analytical tool.
We use non-GAAP financial measures to internally evaluate and analyze financial
results. We believe these non-GAAP financial measures provide investors with
useful supplemental information about the financial performance of our business,
enable comparison of financial results between periods where certain items may
vary independent of business performance, and enable comparison of our financial
results with other public companies, many of which present similar non-GAAP
financial measures. However, the non-GAAP financial measures we present may be
different from those used by other companies, including similarly titled
measures.
We compute these non-GAAP measures by adjusting the applicable GAAP measure to
remove the impact of certain recurring and non-recurring charges and gains and
to adjust for the impact of income tax items related to such adjustments to our
GAAP financial statements. In particular, we exclude amortization of acquired
intangible assets,
acquisition-related expenses relating to our acquisitions of Decipher
Biosciences, HalioDx and C2i Genomics, impairment charges associated with the
nCounter license and other biopharmaceutical services related to HalioDx
intangible assets, all stock-based compensation and certain costs related to
restructuring from all of our non-GAAP financial measures as well as
depreciation and income tax items from our adjusted EBITDA and adjusted EBITDA
as a percentage of revenue. Beginning in the second quarter of 2024, we changed
our non-GAAP policy to exclude all stock-based compensation to align with our
peers and we have also excluded all stock-based compensation from our prior
period non-GAAP financial measures. Management has excluded the effects of these
items in non-GAAP financial measures to help investors gain a better
understanding of the core operating results and future prospects of the company,
consistent with how management measures and forecasts the company's performance,
especially when comparing such results to previous periods or forecasts. The
company encourages investors to carefully consider its results under GAAP,
together with its supplemental non‐GAAP information and the reconciliation
between these presentations. See “Reconciliation of U.S. GAAP to Non-GAAP
Financial Measures” for a reconciliation of each non-GAAP measure presented to
the comparable GAAP financial measure.
VERA…
INC.
COND…
CONS…
STAT…
OF
OPER…
(Una…
(In
thou…
exce…
share Three Nine
and Months Months
per Ended Ended
share Septe… Septem…
amou… 30, 30,
Reve… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Test… $ 146,419 $ 127,7… $ 427,1… $ 357,328
reve…
Prod… 4,626 3,301 12,163 10,479
reve…
Biop…
and 709 815 1,812 8,702
other
reve…
Total 151,754 131,8… 441,1… 376,509
reve…
Cost
of
reve…
(1)
Cost
of 38,477 33,777 108,0… 94,444
test…
reve…
Cost
of 2,766 3,015 7,172 6,186
prod…
reve…
Cost
of
biop… 142 1,091 357 7,361
and
other
reve…
Inta…
asset
amor…
- 3,265 2,707 8,713 7,959
cost
of
reve…
Total
cost 44,650 40,590 124,3… 115,950
of
reve…
Gross 107,104 91,282 316,8… 260,559
prof…
Oper…
expe…
(1)
Rese…
and 32,159 15,981 88,699 49,965
deve…
Sell…
and 28,652 24,455 84,071 74,225
mark…
Gene…
and 29,302 27,278 80,425 93,417
admi…
Impa…
of — — — 20,505
asse…
Inta…
asset
amor… 422 622 1,422 1,865
-
oper…
expe…
Total
oper… 90,535 68,336 254,6… 239,977
expe…
Inco…
from 16,569 22,946 62,195 20,582
oper…
Other
inco… 4,553 -4,057 15,424 6,985
(los…
net
Inco…
befo… 21,122 18,889 77,619 27,567
inco…
taxes
Inco…
tax -10,381 -248 -8,081 2,363
prov…
(ben…
Net $ 31,503 $ 19,137 $ 85,700 $ 25,204
inco…
Earn…
per
shar…
Basic $ 0.39 $ 0.24 $ 1.07 $ 0.32
Dilu… $ 0.38 $ 0.24 $ 1.04 $ 0.32
Shar…
used
to
comp…
earn…
per
comm…
shar…
Basic 80,500… 78,72… 80,00… 78,384…
Dilu… 82,783… 79,69… 82,20… 79,946…
1. Cost of revenue, research and development, sales and marketing and general
and administrative expenses include the following stock-based compensation
related expenses:
Three Nine
Months Months
Ended Ended
September Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Cost of $ 995 $ 540 $ 3,054 $ 1,668
revenue
Resear…
and 2,742 1,949 8,340 6,023
develo…
Selling
and 2,734 2,102 7,839 6,258
market…
General
and 7,488 6,166 21,573 18,751
admini…
Total
stock-… $ 13,959 $ 10,757 $ 40,806 $ 32,700
compen…
expense
VERAC…
INC.
CONDE…
CONSO…
STATE…
OF
COMPR…
INCOME
(Unau…
(In
thous…
Three Nine
Months Months
Ended Ended
Septem… Septem…
30, 30,
2026 2025 2026 2025
Net $ 31,503 $ 19,137 $ 85,700 $ 25,204
income
Other
compr…
income
(loss…
Change
in
curre… -122 -4,556 151 19,575
trans…
adjus…
Relea…
of
accum… — 8,295 — 8,295
trans…
adjus…
Other
compr… -122 3,739 151 27,870
income
(loss)
Net
compr… $ 31,381 $ 22,876 $ 85,851 $ 53,074
income
VERACYTE, INC.
CONDENSED
CONSOLIDATED BALANCE
SHEETS
(In thousands) September 30, December 31,
Assets 2026 2025
Current assets: (Unaudited) (See Note 1)
──────────────────────────────────────────────────────────────────────────────
Cash and cash $ 199,828 $ 362,578
equivalents
Short-term 170,704 50,311
investments
Accounts receivable 56,788 44,660
Supplies 25,818 20,546
Prepaid expenses and
other current 14,740 10,281
assets
Total current assets 467,878 488,376
Property, plant and 24,870 22,192
equipment, net
Right-of-use assets, 35,097 36,599
operating leases
Intangible assets, 184,883 89,148
net
Goodwill 855,575 767,154
Restricted cash 1,646 1,648
Other assets 3,307 902
Total assets $ 1,573,256 $ 1,406,019
Liabilities and
Stockholders’ Equity
Current liabilities:
Accounts payable $ 9,710 $ 4,593
Accrued liabilities 60,087 48,801
Current portion of 864 1,160
deferred revenue
Current portion of
acquisition-related 6,734 1,332
contingent
consideration
Current portion of
operating lease 6,814 4,051
liabilities
Total current 84,209 59,937
liabilities
Deferred tax 1,616 646
liabilities
Acquisition-related
contingent 17,245 257
consideration, net of
current portion
Operating lease
liabilities, net of 33,922 35,603
current portion
Other liabilities 3,000 —
Total liabilities 139,992 96,443
Total stockholders’ 1,433,264 1,309,576
equity
Total liabilities and
stockholders’ $ 1,573,256 $ 1,406,019
equity
1. The condensed
consolidated balance
sheet at December 31,
2025 has been
derived from the
audited financial
statements at that
date included in the
company's Annual
Report on Form 10-K
for
the year ended
December 31, 2025,
filed
with the Securities
and Exchange
Commission on
February 26, 2026.
VERACYTE, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF CASH
FLOWS
(Unaudited) Nine Months Ended
(In thousands) September 30,
Operating activities 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 85,700 $ 25,204
Adjustments to
reconcile net income
to
net cash provided by
operating
activities:
Depreciation and 16,247 16,117
amortization
Loss on disposal of
property, plant and 367 15
equipment
Stock-based 40,806 32,700
compensation
Deferred income taxes -11,599 -13
Noncash lease expense 2,088 2,289
Revaluation of
acquisition-related -1,110 -2,713
contingent
consideration
Effect of foreign -23 -3,845
currency on operations
Amortization of
discount on short-term -2,380 -2,619
investments
Impairment loss — 20,505
Non-cash loss on
deconsolidation of — 3,863
subsidiary
Changes in operating
assets and
liabilities:
Accounts receivable -11,963 -3,858
Supplies -3,435 -2,642
Prepaid expenses and
other current -4,112 -6,416
assets
Other assets -771 331
Operating lease 496 -1,681
liabilities
Accounts payable 5,522 -547
Accrued liabilities 5,466 7,034
and deferred revenue
Net cash provided by
operating 121,299 83,724
activities
Investing activities
Business acquisitions,
net of cash -153,190 —
acquired
Purchase of short-term -234,997 -99,998
investments
Proceeds from maturity
of short-term 116,984 102,116
investments
Issuance of loan -1,622 —
receivable
Purchases of property,
plant and -8,155 -5,897
equipment
Net cash used in -280,980 -3,779
investing activities
Financing activities
Payment of taxes on
vested restricted -17,462 -14,645
stock units
Proceeds from the
exercise of common
stock options and 14,493 10,572
employee stock
purchases
Net cash used in -2,969 -4,073
financing activities
(Decrease) increase in
cash, cash -162,650 75,872
equivalents and
restricted cash
Effect of foreign
currency on cash, cash -102 707
equivalents and
restricted cash
Net (decrease)
increase in cash, cash -162,752 76,579
equivalents and
restricted cash
Cash, cash equivalents
and restricted 364,226 240,631
cash at beginning of
period
Cash, cash equivalents
and restricted $ 201,474 $ 317,210
cash at end of period
CASH, CASH EQUIVALENTS
AND RESTRICTED
CASH
(Unaudited)
(In thousands)
September 30, December 31,
2026 2025
Cash and cash equivalents $ 199,828 $ 362,578
Restricted cash 1,646 1,648
Total cash, cash
equivalents and $ 201,474 $ 364,226
restricted cash
VER…
INC.
REC…
OF
U.S.
GAAP
to
NON…
FIN…
MEA…
(Un…
(In
tho…
Rec… Three Nine
of Mont… Mont…
Non… Ended Ended
Cost Sept… Sept…
of 30, 30,
Rev… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
cost
of $ 38,4… $ 33,… $ 108… $ 94,4…
tes…
rev…
Sto…
com… -994 -555 -3,… -1,5…
exp…
Acq…
rel… -131 — -131 —
exp…
(1)
Oth…
adj… -316 — -954 —
(2)
Non…
cost
of $ 37,0… $ 33,… $ 103… $ 92,9…
tes…
rev…
GAAP
cost
of 2,766 3,0… 7,1… 6,186
pro…
rev…
Sto…
com… -1 — -2 -2
exp…
Acq…
rel… — — — —
exp…
(1)
Oth…
adj… — -1,… 11 -1,4…
(2)
Non…
cost
of $ 2,765 $ 1,5… $ 7,1… $ 4,734
pro…
rev…
GAAP
cost
of
bio… 142 1,0… 357 7,361
and
oth…
rev…
Sto…
com… — 15 — -123
exp…
Acq…
rel… — — — —
exp…
(1)
Oth…
adj… — — — —
(2)
Non…
cost
of
bio… $ 142 $ 1,1… $ 357 $ 7,238
and
oth…
rev…
Rec…
of
Non…
Gro…
Mar…
GAAP
Gro… $ 107,… $ 91,… $ 316… $ 260,…
Pro…
GAAP
Gro… 70.6 % 69.2 % 71.8 % 69.2 %
Mar…
Amo…
of 3,265 2,7… 8,7… 7,959
int…
ass…
Sto…
com… 995 540 3,0… 1,668
exp…
Acq…
rel… 131 — 131 —
exp…
(1)
Oth…
adj… 316 1,4… 943 1,450
(2)
Non…
Gro… $ 111,… $ 95,… $ 329… $ 271,…
Pro…
Non…
Gro… 73.7 % 72.8 % 74.7 % 72.1 %
Mar…
1.I…
tra…
exp…
For
the
thr…
mon…
and
nine
mon…
end…
Sep…
30,
202…
adj…
con…
pri…
of
tra…
exp…
ass…
with
acq…
act…
($0…
2.F…
the
thr…
mon…
end…
Sep…
30,
202…
adj…
inc…
the
imp…
of
Non…
adj…
on
IT/…
all…
($0…
mil…
For
the
thr…
mon…
end…
Sep…
30,
202…
adj…
inc…
exp…
rel…
to
Ver…
SAS
inv…
rev…
For
the
nine
mon…
end…
Sep…
30,
202…
adj…
inc…
the
imp…
of
Non…
adj…
on
IT/…
all…
($0…
mil…
par…
off…
by
exp…
rel…
to
the
res…
of
Ver…
SAS.
For
the
nine
mon…
end…
Sep…
30,
202…
adj…
inc…
exp…
rel…
to
Ver…
SAS
inv…
rev…
VERA…
INC.
RECO…
OF
U.S.
GAAP
to
NON-…
FINA…
MEAS…
(Una…
(In
thou… Three Nine
Reco… Months Months
of Ended Ended
Non-… Septem… Septe…
Oper… 30, 30,
Expe… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
rese… $ 32,159 $ 15,981 $ 88,699 $ 49,965
and
deve…
Stoc…
comp… -2,742 -1,949 -8,340 -6,023
expe…
Acqu…
rela… -1 — -1 —
expe…
(1)
Other
adju… -176 — -652 —
(2)
Non-…
rese… $ 29,240 $ 14,032 $ 79,706 $ 43,942
and
deve…
GAAP
sales $ 28,652 $ 24,455 $ 84,071 $ 74,225
and
mark…
Stoc…
comp… -2,734 -2,102 -7,839 -6,258
expe…
Acqu…
rela… — — — —
expe…
(1)
Other
adju… -45 — -124 —
(2)
Non-…
sales $ 25,873 $ 22,353 $ 76,108 $ 67,967
and
mark…
GAAP
gene… $ 29,302 $ 27,278 $ 80,425 $ 93,417
and
admi…
Stoc…
comp… -7,488 -6,166 -21,573 -18,7…
expe…
Acqu…
rela… -1,321 -166 -635 -593
expe…
(1)
Other
adju… -2,694 1,308 -6,516 -6,530
(2)
Non-…
gene… $ 17,799 $ 22,254 $ 51,701 $ 67,543
and
admi…
GAAP
total $ 90,535 $ 68,336 $ 254,617 $ 239,9…
oper…
expe…
Amor…
of -422 -622 -1,422 -1,865
inta…
asse…
Stoc…
comp… -12,9… -10,217 -37,752 -31,0…
expe…
Acqu…
rela… -1,322 -166 -636 -593
expe…
(1)
Other
adju… -2,915 1,308 -7,292 -27,0…
(2)
Non-…
total $ 72,912 $ 58,639 $ 207,515 $ 179,4…
oper…
expe…
1.Includes transaction-related expenses as well as
post-combination compensation expenses. For the
three months ended September 30, 2026, adjustments
consist primarily of transaction-related expenses
associated with the acquisition of Convergent
Genomics, Inc. ("Convergent") ($1.7 million)
partially offset with contingent consideration
related to the NanoString Technologies, Inc.
("NanoString") transaction ($0.4 million). For the
three months ended September 30, 2025, adjustments
consist primarily of transaction-related expenses
associated with contingent consideration related
to NanoString and contingent consideration
associated with the acquisition of C2i Genomics.
For the nine months ended September 30, 2026,
adjustments consist primarily of
transaction-related expenses associated with the
acquisition of Convergent ($1.7 million) partially
offset with NanoString contingent consideration
($1.1 million). For the nine months ended
September 30, 2025, adjustments consist primarily
of transaction-related expenses associated with
the acquisition of C2i Genomics ($1.6 million)
partially offset by NanoString contingent
consideration ($1.0 million).
2.For the three months ended September 30, 2026,
adjustments consist primarily of expenses related
to legal proceedings ($3.2 million), partially
offset by the impact of Non-GAAP adjustments on
IT/Facilities allocations ($0.3 million). For the
three months ended September 30, 2025, adjustments
primarily include a vendor legal settlement ($2.8
million) partially offset by expenses related to
the restructuring and liquidation proceedings of
Veracyte SAS ($1.0 million) and other legal
proceedings ($0.5 million). For the nine months
ended September 30, 2026, adjustments consist
primarily of expenses related to legal proceedings
($4.9 million), expenses related to the assessment
of licensing and strategic investments ($3.0
million), and expenses related to the liquidation
proceedings of Veracyte SAS ($0.3 million),
partially offset by the impact of Non-GAAP
adjustments on IT/Facilities allocations ($0.9
million). For the nine months ended September 30,
2025, adjustments include additional expenses
related to Veracyte SAS impairment loss ($20.5
million) and related to the restructuring and
liquidation proceedings of Veracyte SAS ($8.0
million), partially offset by adjustments related
to restructuring costs ($0.1 million).
VER…
INC.
REC…
OF
U.S.
GAAP
to
NON…
FIN…
MEA…
(Un…
(In Three Nine
tho… Mont… Mont…
Rec… Ended Ended
of Sept… Sept…
Adj… 30, 30,
EBI… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
Net $ 31,5… $ 19,… $ 85,… $ 25,2…
Inc…
(Lo…
GAAP
Net
Inc…
(Lo… 20.8 % 14.5 % 19.4 % 6.7 %
as a
% of
Rev…
Amo…
of 3,687 3,3… 10,… 9,824
int…
ass…
Dep… 2,293 1,9… 6,1… 6,293
exp…
Sto…
com… 13,9… 10,… 40,… 32,7…
exp…
Acq…
rel… 1,453 166 767 593
exp…
(1)
Oth…
exp…
(in… -4,5… -3,… -11… -9,6…
net
(2)
Oth…
adj… 3,231 8,1… 4,4… 32,8…
(3)
Inc…
tax -10,… -248 -8,… 2,363
exp…
(be…
Adj… $ 41,2… $ 39,… $ 127… $ 100,…
EBI…
Adj…
EBI…
as a 27.2 % 30.1 % 29.0 % 26.6 %
% of
Rev…
Rec…
of
Non…
Net
Inc…
(Lo…
GAAP
Net $ 31,5… $ 19,… $ 85,… $ 25,2…
Inc…
(Lo…
Amo…
of 3,687 3,3… 10,… 9,824
int…
ass…
Sto…
com… 13,9… 10,… 40,… 32,7…
exp…
Acq…
rel… 1,453 166 767 593
exp…
(1)
Oth…
adj… 3,231 8,1… 4,4… 32,8…
(3)
Tax
adj… -11,… -565 -13… -807
(4)
Non…
Net $ 41,8… $ 40,… $ 128… $ 100,…
Inc…
Rec…
of
Non…
Ear…
per
Sha…
Dil…
ear…
per $ 0.38 $ 0.24 $ 1.04 $ 0.32
sha…
GAAP
Amo…
of 0.04 0.04 0.12 0.12
int…
ass…
Sto…
com… 0.17 0.13 0.50 0.41
exp…
Acq…
rel… 0.02 — 0.01 0.01
exp…
(1)
Oth…
adj… 0.04 0.10 0.05 0.41
(3)
Tax
adj… -0.14 -0.… -0.… -0.01
(4)
Rou…
and
imp… — 0.01 — —
of
dil…
sha…
Dil…
ear…
per $ 0.51 $ 0.51 $ 1.56 $ 1.26
sha…
non…
Wei…
ave…
sha…
out…
used
in
com…
dil…
ear…
per
sha…
Dil… 82,7… 79,… 82,… 79,9…
GAAP
Dil…
eff…
of — — — —
equ…
awa…
(5)
Dil… 82,7… 79,… 82,… 79,9…
non…
1.Includes transaction-related expenses as well as
post-combination compensation expenses. For the
three months ended September 30, 2026, adjustments
consist primarily of transaction-related expenses
associated with the acquisition activities ($1.9
million), partially offset by contingent
consideration related to the NanoString
transaction ($0.4 million). For the three months
ended September 30, 2025, adjustments consist
primarily of transaction-related expenses
associated with contingent consideration related
to NanoString and contingent consideration
associated with the acquisition of C2i Genomics.
For the nine months ended September 30, 2026,
adjustments consist primarily of
transaction-related expenses associated with the
acquisition activities ($1.9 million), partially
offset with NanoString contingent consideration
($1.1 million). For the nine months ended
September 30, 2025, adjustments consist primarily
of transaction-related expenses associated with
the acquisition of C2i Genomics ($1.6 million)
partially offset by NanoString contingent
consideration ($1.0 million).
2.Includes interest income and income related to
research tax credits.
3.For the three months ended September 30, 2026,
adjustments consist primarily of expenses related
to legal proceedings ($3.2 million). For the three
months ended September 30, 2025, adjustments
primarily include expenses related to the
exclusion of unrealized loss related to Veracyte
SAS deconsolidation ($6.7 million), the exclusion
of unrealized loss associated with foreign
exchange impact on stock-based compensation and
intercompany loans ($1.3 million), the
restructuring and liquidation proceedings of
Veracyte SAS ($2.4 million), and other legal
proceedings ($0.5 million), partially offset by
vendor legal settlement ($2.8 million). For the
nine months ended September 30, 2026, adjustments
primarily include expenses related to legal
proceedings ($4.9 million), expenses related to
the assessment of licensing and strategic
investments ($3.0 million), expenses related to
the liquidation proceedings of Veracyte SAS ($0.3
million), and losses related to asset disposition
($0.4 million), partially offset by adjustments
related to the restructuring and liquidation
proceedings of Veracyte SAS ($4.2 million). For
the nine months ended September 30, 2025,
adjustments include additional expenses related to
Veracyte SAS impairment loss ($20.5 million) and
Veracyte SAS investment review ($8.0 million),
partially offset by adjustments related to
restructuring costs ($0.1 million) and additional
exclusion of unrealized gains associated with
foreign exchange impacts on stock-based
compensation and intercompany loans ($3.6
million).
4.Incremental non-GAAP tax expense reflects the
tax impact of the non-GAAP adjustments listed.
5.In those periods in which GAAP net (loss) income
is negative and non-GAAP net (loss) income is
positive, non-GAAP diluted weighted average shares
outstanding includes potentially dilutive common
shares from equity awards as determined using the
treasury stock method.
# # #
Investors:
Kelly Gura
[email protected]
Media:
Molly Cornbleet
[email protected]
+1-650-351-8780